(19)
(11) EP 2 623 604 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
22.04.2015 Bulletin 2015/17

(45) Mention of the grant of the patent:
25.02.2015 Bulletin 2015/09

(21) Application number: 12000703.4

(22) Date of filing: 02.02.2012
(51) International Patent Classification (IPC): 
C12N 15/86(2006.01)
A61K 48/00(2006.01)

(54)

Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis

Biologisches Abgabe- und Expressionssystem auf Adenovirusbasis zur Verwendung bei der Behandlung von Osteoarthrose

Administration biologique à base adénovirale et système d'expression pour une utilisation dans le traitement de l'osteoartritis


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(43) Date of publication of application:
07.08.2013 Bulletin 2013/32

(73) Proprietor: Baylor College of Medicine
Houston, TX 77030 (US)

(72) Inventors:
  • Lee, Brendan
    Houston, Texas 77030 (US)
  • Guse, Kilian
    00150 Helsinki (FI)
  • Ruan, Zhechao
    Houston, TX 77057 (US)

(74) Representative: Patentanwälte Dr. Keller, Schwertfeger 
Westring 17
76829 Landau
76829 Landau (DE)


(56) References cited: : 
   
  • BAKKER A C ET AL: "C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen-induced arthritis superior to cytomegalovirus-regulated expression of the same transgene.", ARTHRITIS AND RHEUMATISM JUN 2002 LNKD- PUBMED:12115199, vol. 46, no. 6, June 2002 (2002-06), pages 1661-1670, XP002675514, ISSN: 0004-3591
  • PALMER DONNA ET AL: "Improved system for helper-dependent adenoviral vector production.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY NOV 2003 LNKD- PUBMED:14599819, vol. 8, no. 5, November 2003 (2003-11), pages 846-852, XP002675515, ISSN: 1525-0016
  • TOIETTA GABRIELE ET AL: "Generation of helper-dependent adenoviral vectors by homologous recombination.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY FEB 2002 LNKD- PUBMED:11829528, vol. 5, no. 2, February 2002 (2002-02), pages 204-210, XP002675516, ISSN: 1525-0016
  • KHOURY M ET AL: "Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis.", THE JOURNAL OF GENE MEDICINE JUL 2007 LNKD- PUBMED:17514770, vol. 9, no. 7, July 2007 (2007-07), pages 596-604, XP002675517, ISSN: 1099-498X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).